These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24563588)

  • 1. Adverse drug reaction and concepts of drug safety in Ayurveda: An overview.
    Ajanal M; Nayak S; Prasad BS; Kadam A
    J Young Pharm; 2013 Dec; 5(4):116-20. PubMed ID: 24563588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance study of Ayurvedic medicine in Ayurvedic Teaching Hospital: A prospective survey study.
    Ajanal MN; Nayak SU; Kadam AP; Prasad BS
    Ayu; 2015; 36(2):130-7. PubMed ID: 27011712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions.
    Neubert A; Dormann H; Prokosch HU; Bürkle T; Rascher W; Sojer R; Brune K; Criegee-Rieck M
    Br J Clin Pharmacol; 2013 Sep; 76 Suppl 1(Suppl 1):69-77. PubMed ID: 23586589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why and how? Addressing to the two most pertinent questions about pharmacovigilance in Ayurveda.
    Rastogi S
    Int J Ayurveda Res; 2011 Jan; 2(1):48-52. PubMed ID: 21897643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.
    Sartori D; Aronson JK; Onakpoya IJ
    Syst Rev; 2020 Aug; 9(1):180. PubMed ID: 32791982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations.
    Chaudhary A; Singh N; Kumar N
    J Ayurveda Integr Med; 2010 Oct; 1(4):251-6. PubMed ID: 21731371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study-study protocol.
    Dweik RA; Yaya S; Stacey D; Kohen D
    Springerplus; 2016; 5():213. PubMed ID: 27026907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
    Inch J; Watson MC; Anakwe-Umeh S
    Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary and alternative medicine: Pharmacovigilance in Malaysia and predictors of serious adverse reactions.
    Shaikh Abdul Rahman S; Aziz Z
    J Clin Pharm Ther; 2020 Oct; 45(5):946-958. PubMed ID: 31925959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An 'Ayurveda-Biology' platform for integrative diabetes management.
    Thottapillil A; Kouser S; Kukkupuni SK; Vishnuprasad CN
    J Ethnopharmacol; 2021 Mar; 268():113575. PubMed ID: 33181283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication safety knowledge, attitude, and practice among hospital pharmacists in Lebanon.
    Hallit S; Hajj A; Shuhaiber P; Iskandar K; Ramia E; Sacre H; Salameh P;
    J Eval Clin Pract; 2019 Apr; 25(2):323-339. PubMed ID: 30592116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis.
    Ribeiro-Vaz I; Silva AM; Costa Santos C; Cruz-Correia R
    BMC Med Inform Decis Mak; 2016 Mar; 16():27. PubMed ID: 26926375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.